TY - JOUR ID - 37195 TI - PI3K/Akt/mTOR and CDK4 combined inhibition enhanced apoptosis of thyroid cancer cell lines JO - International Journal of Advanced Biological and Biomedical Research JA - IJABBR LA - en SN - 2383-2762 AU - Hamidipour, Neda AU - Fazeli, Mehdi AU - Hedayati, Mehdi AU - Dehghani, Mohsen AU - Gerami, Razieh AD - Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran AD - 2. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Rayan Pars Pharmacutical Industry, shiraz, Iran Y1 - 2020 PY - 2020 VL - 8 IS - 2 SP - 214 EP - 224 KW - Thyroid cancer KW - Carcinoma KW - Apoptosis KW - NVP-BEZ235 KW - PD-332991 DO - 10.33945/SAMI/IJABBR.2020.2.10 N2 - Introduction Thyroid cancer is a malignant disease with poor prognosis. The PI3K/Akt/mTOR and Cyclin-Dependent Kinase 4 (CDK4) pathways are vital regulators of tumor cell proliferation and survival. Therefore the present study was designed to use dual inhibition of such pathways to kill thyroid cancer cells. Methods and materials The effects of each inhibitors on human ATC and BCPAP cell lines were evaluated by MTT assay. The suitable concentrations of inhibitors were determined and synergistic effects of such inhibitors were evaluated by bax/bcl-2 mRNA ratio, Caspase-3, and Caspase-9 activity assay as well as Akt, mTOR, and CDK4. Results:Our finding showed that both ATC and BCPAP cell proliferation is significantly inhibited by PD-332991(PD) and NVP-BEZ235 (NVP) in a time and concentration-dependent manner (P UR - https://www.ijabbr.com/article_37195.html L1 - https://www.ijabbr.com/article_37195_0e855a37795618c586a97567e37a95dc.pdf ER -